[PRNewswire] Pneuma Respiratory and Leads Biolabs, Inc. Announce Partnership
(BOONE, North Carolina, May 15, 2019 PRNewswire=연합뉴스) Pneuma Respiratory, Inc., developer of a proprietary breath-activated digital inhaler (BDI), and Leads Biolabs Inc. announce an agreement granting Pneuma an exclusive license to develop Leads Biolabs' panel of immuno-oncology monoclonal antibodies and fusion protein molecules for the pulmonary delivery of Leads' antibodies and molecules. Using Pneuma's digital inhaler platform, the agreement provides access to the untapped potential of pulmonary delivery of Leads' immuno-oncology therapies in the treatment of oncologic or immune-mediated lung diseases.
In a recent publication, Pneuma announced the completion of a study demonstrating the feasibility of antibody delivery to the lungs via its digital inhaler platform. This study, conducted in an animal model, indicates that the Pneuma digital inhaler platform may provide a method for the pulmonary delivery of monoclonal antibody therapies, enabling the targeted treatment of oncologic or immune-mediated lung diseases.
"This collaboration is an exciting development for the field of immuno-oncology," said Ronald Bukowski, MD, physician emeritus, Cleveland Clinic Foundation. "Approaches utilizing the regional administration of novel checkpoint inhibitors may provide new treatment opportunities for patients with a variety of malignancies."
"We are pleased to enter into a license agreement for Leads Biolabs monoclonal antibody portfolio," said Pneuma Chief Executive Officer and co-founder Eric Hunter. "We look forward to working with their team to conduct studies that may lead to positive change in the future treatment of non-small cell lung cancer."
Dr. Xiaoqiang Kang, Chairman and CEO of Leads Biolabs, said: "We are very excited to have this license agreement with Pneuma Respiratory. The commitment by a leader in digital pulmonary delivery of drugs is an endorsement of the value of our portfolio. We believe that Pneuma's digital inhaler technology combined with our antibody drugs will create very exciting new opportunities for both companies. We look forward to working with Pneuma to move our candidates into the clinic as quickly as possible."
About Pneuma Respiratory:
Launched in 2015, Pneuma Respiratory is a pharmaceutical company based in Boone, North Carolina. With a global team of researchers, physicians, designers and engineers, Pneuma has created the first fully integrated digital breath-activated inhaler. This inhaled delivery system includes digital micro-fluidics integrated with Bluetooth technology capable of providing feedback on drug delivery to patients, family members, and health care providers. Using Pneuma's digital droplet ejector technology, Pneuma's device has the potential to ultimately deliver a spectrum of novel therapies, including biologics, to the lungs. The first breath-activated digital inhaler (BDI) is currently in use for investigational purposes only and is not yet commercially available. For more information, please visit www.pneumarespiratory.com.
About Leads Biolabs, Inc.:
Leads Biolabs, Inc., a Maryland Corporation, is the fully-owned subsidiary of a US-Sino joint venture company, Nanjing Leads Biolabs Co., Ltd. based in Nanjing, China. Leads Biolabs is an innovation-driven biopharmaceutical company with a rich portfolio of more than 10 novel mono-targeted or bispecific antibody drug projects for cancer immunotherapy and other major diseases to fulfill unmet medical needs. For more information, please visit www.leadsbiolabs.com.
PRIMARY MEDIA CONTACT:
Christy Anglin
canglin@pneumarespiratory.com
Logo - https://mma.prnewswire.com/media/887236/Pneuma_Respiratory_Logo.jpg
Source: Pneuma Respiratory
[편집자 주] 본고는 자료 제공사에서 제공한 것으로, 연합뉴스는 내용에 대해 어떠한 편집도 하지 않았음을 밝혀 드립니다.
(끝)
<저작권자(c) 연합뉴스, 무단 전재-재배포 금지>
(BOONE, North Carolina, May 15, 2019 PRNewswire=연합뉴스) Pneuma Respiratory, Inc., developer of a proprietary breath-activated digital inhaler (BDI), and Leads Biolabs Inc. announce an agreement granting Pneuma an exclusive license to develop Leads Biolabs' panel of immuno-oncology monoclonal antibodies and fusion protein molecules for the pulmonary delivery of Leads' antibodies and molecules. Using Pneuma's digital inhaler platform, the agreement provides access to the untapped potential of pulmonary delivery of Leads' immuno-oncology therapies in the treatment of oncologic or immune-mediated lung diseases.
In a recent publication, Pneuma announced the completion of a study demonstrating the feasibility of antibody delivery to the lungs via its digital inhaler platform. This study, conducted in an animal model, indicates that the Pneuma digital inhaler platform may provide a method for the pulmonary delivery of monoclonal antibody therapies, enabling the targeted treatment of oncologic or immune-mediated lung diseases.
"This collaboration is an exciting development for the field of immuno-oncology," said Ronald Bukowski, MD, physician emeritus, Cleveland Clinic Foundation. "Approaches utilizing the regional administration of novel checkpoint inhibitors may provide new treatment opportunities for patients with a variety of malignancies."
"We are pleased to enter into a license agreement for Leads Biolabs monoclonal antibody portfolio," said Pneuma Chief Executive Officer and co-founder Eric Hunter. "We look forward to working with their team to conduct studies that may lead to positive change in the future treatment of non-small cell lung cancer."
Dr. Xiaoqiang Kang, Chairman and CEO of Leads Biolabs, said: "We are very excited to have this license agreement with Pneuma Respiratory. The commitment by a leader in digital pulmonary delivery of drugs is an endorsement of the value of our portfolio. We believe that Pneuma's digital inhaler technology combined with our antibody drugs will create very exciting new opportunities for both companies. We look forward to working with Pneuma to move our candidates into the clinic as quickly as possible."
About Pneuma Respiratory:
Launched in 2015, Pneuma Respiratory is a pharmaceutical company based in Boone, North Carolina. With a global team of researchers, physicians, designers and engineers, Pneuma has created the first fully integrated digital breath-activated inhaler. This inhaled delivery system includes digital micro-fluidics integrated with Bluetooth technology capable of providing feedback on drug delivery to patients, family members, and health care providers. Using Pneuma's digital droplet ejector technology, Pneuma's device has the potential to ultimately deliver a spectrum of novel therapies, including biologics, to the lungs. The first breath-activated digital inhaler (BDI) is currently in use for investigational purposes only and is not yet commercially available. For more information, please visit www.pneumarespiratory.com.
About Leads Biolabs, Inc.:
Leads Biolabs, Inc., a Maryland Corporation, is the fully-owned subsidiary of a US-Sino joint venture company, Nanjing Leads Biolabs Co., Ltd. based in Nanjing, China. Leads Biolabs is an innovation-driven biopharmaceutical company with a rich portfolio of more than 10 novel mono-targeted or bispecific antibody drug projects for cancer immunotherapy and other major diseases to fulfill unmet medical needs. For more information, please visit www.leadsbiolabs.com.
PRIMARY MEDIA CONTACT:
Christy Anglin
canglin@pneumarespiratory.com
Logo - https://mma.prnewswire.com/media/887236/Pneuma_Respiratory_Logo.jpg
Source: Pneuma Respiratory
[편집자 주] 본고는 자료 제공사에서 제공한 것으로, 연합뉴스는 내용에 대해 어떠한 편집도 하지 않았음을 밝혀 드립니다.
(끝)
<저작권자(c) 연합뉴스, 무단 전재-재배포 금지>
관련뉴스
